Multiple myeloma (MM), a plasma cell-derived malignant hematological disease, is often treated with bortezomib, a highly effective first-generation proteasome inhibitor. However, resistance to bortezomib is a common occurrence. Profilin 1 (PFN1), a cytoskeleton-related gene known to promote autophagy in MM, induces this resistance to bortezomib, but it is unclear why. The aim of this study was to uncover the molecular mechanisms involved in bortezomib resistance, considering not only PFN1, but also CD138, a transmembrane proteoglycan that is a hallmark of plasma and MM cells. We detected CD138 and PFN1 in the bone marrow of patients with MM immunohistochemically. We also studied the Gene Expression Omnibus (GEO) data and found that CD138 was associated with PFN1 and autophagy. We then evaluated their expression in an MM cell line via western blot analysis, immunofluorescence assay, and flow cytometry
constructed PFN1-overexpressing and -knockdown cell lines
and detected ubiquitinated CD138 in the cells of both cell lines. Overexpression of PFN1 or PFN1-induced autophagy downregulated CD138 expression. Owing to the stemness and resistance of CD138